These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 35007624

  • 1. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
    Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM.
    J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
    [Abstract] [Full Text] [Related]

  • 2. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.
    Chupp G, Alobid I, Lugogo NL, Kariyawasam HH, Bourdin A, Chaker AM, Smith SG, Sousa AR, Mayer B, Chan RH, Matucci A.
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3504-3512.e2. PubMed ID: 37586475
    [Abstract] [Full Text] [Related]

  • 3. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
    Desrosiers M, Diamant Z, Castelnuovo P, Hellings PW, Han JK, Peters AT, Silver J, Smith SG, Fuller A, Sousa AR, Chan RH, Gevaert P, SYNAPSE study investigators.
    Int Forum Allergy Rhinol; 2024 Jan; 14(1):18-31. PubMed ID: 37345861
    [Abstract] [Full Text] [Related]

  • 4. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C, SYNAPSE study investigators.
    Lancet Respir Med; 2021 Oct; 9(10):1141-1153. PubMed ID: 33872587
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP.
    Lancet; 2019 Nov 02; 394(10209):1638-1650. PubMed ID: 31543428
    [Abstract] [Full Text] [Related]

  • 6. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.
    Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, Coste A, Sousa AR, Howarth PH, Benson VS, Mayer B, Yancey SW, Chan R, Gane SB.
    Allergy; 2023 Mar 02; 78(3):812-821. PubMed ID: 35822924
    [Abstract] [Full Text] [Related]

  • 7. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
    Fokkens W, Trigg A, Lee SE, Chan RH, Diamant Z, Hopkins C, Howarth P, Lund V, Mayer B, Sousa AR, Yancey S, Tabberer M, SYNAPSE study group.
    J Patient Rep Outcomes; 2023 Jan 20; 7(1):4. PubMed ID: 36662344
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
    Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, Tversky JR, Barker P, Cohen D, Emson C, Martin UJ, Shih VH, Necander S, Kreindler JL, Jison M, Werkström V.
    J Allergy Clin Immunol; 2022 Apr 20; 149(4):1309-1317.e12. PubMed ID: 34599979
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia.
    Fujieda S, Wang C, Yoshikawa M, Asako M, Suzaki I, Bachert C, Han JK, Fuller A, Baylis L, Su L, Sasaki E, Sousa AR, Chan R, Zhang L.
    Rhinology; 2024 Oct 01; 62(5):576-589. PubMed ID: 39058315
    [Abstract] [Full Text] [Related]

  • 12. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A, Tremante E, D'Amato M, Calabrese C, Casella C, Maniscalco M, Poto R, Brancaccio R, Boccia M, Martino M, Imperatore C, Spadaro G.
    Ther Adv Respir Dis; 2021 Oct 01; 15():17534666211009398. PubMed ID: 33910399
    [No Abstract] [Full Text] [Related]

  • 13. The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA.
    Mullol J, Fokkens WJ, Smith SG, Keeley T, Zhang L, Howarth P, Chan RH, Bachert C.
    Rhinology; 2024 Sep 27. PubMed ID: 39323188
    [Abstract] [Full Text] [Related]

  • 14. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
    Buchheit KM, Lewis E, Gakpo D, Hacker J, Sohail A, Taliaferro F, Berreondo Giron E, Asare C, Vukovic M, Bensko JC, Dwyer DF, Shalek AK, Ordovas-Montanes J, Laidlaw TM.
    J Allergy Clin Immunol; 2021 Aug 27; 148(2):574-584. PubMed ID: 34144111
    [Abstract] [Full Text] [Related]

  • 15. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
    Sindwani R, Han JK, Soteres DF, Messina JC, Carothers JL, Mahmoud RA, Djupesland PG.
    Am J Rhinol Allergy; 2019 Jan 27; 33(1):69-82. PubMed ID: 30477309
    [Abstract] [Full Text] [Related]

  • 16. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M.
    J Allergy Clin Immunol Pract; 2019 Feb 27; 7(2):589-596.e3. PubMed ID: 30193936
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C, Khan AH, Lee SE, Hopkins C, Peters AT, Fokkens W, Praestgaard A, Radwan A, Nash S, Jacob-Nara JA, Deniz Y, Rowe PJ.
    Int Forum Allergy Rhinol; 2024 Mar 27; 14(3):668-678. PubMed ID: 37548085
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
    Mullol J, Lund VJ, Wagenmann M, Han JK, Sousa AN, Smith SG, Mayer B, Chan RH, Fokkens WJ.
    Rhinology; 2024 Jun 01; 62(3):320-329. PubMed ID: 38217844
    [Abstract] [Full Text] [Related]

  • 19. Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience.
    Santus P, Saad M, Casartelli A, Lorusso R, Milani L, Danzo F, Busatto P, Radovanovic D.
    Ann Med; 2024 Dec 01; 56(1):2407523. PubMed ID: 39373532
    [Abstract] [Full Text] [Related]

  • 20. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery.
    Silver J, Deb A, Laliberté F, Gao C, Bhattacharyya N.
    Int Forum Allergy Rhinol; 2024 Jan 01; 14(1):5-17. PubMed ID: 37365852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.